|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRMT6 |
Gene summary for TRMT6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRMT6 | Gene ID | 51605 |
| Gene name | tRNA methyltransferase 6 non-catalytic subunit | |
| Gene Alias | CGI-09 | |
| Cytomap | 20p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001510 | UniProtAcc | Q9UJA5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51605 | TRMT6 | LZE2T | Human | Esophagus | ESCC | 2.47e-07 | 3.05e-01 | 0.082 |
| 51605 | TRMT6 | LZE4T | Human | Esophagus | ESCC | 5.16e-08 | 2.47e-01 | 0.0811 |
| 51605 | TRMT6 | LZE7T | Human | Esophagus | ESCC | 2.13e-04 | 5.02e-01 | 0.0667 |
| 51605 | TRMT6 | LZE8T | Human | Esophagus | ESCC | 1.68e-07 | 7.61e-02 | 0.067 |
| 51605 | TRMT6 | LZE24T | Human | Esophagus | ESCC | 4.17e-13 | 1.26e-01 | 0.0596 |
| 51605 | TRMT6 | LZE21T | Human | Esophagus | ESCC | 4.08e-02 | -5.24e-02 | 0.0655 |
| 51605 | TRMT6 | P2T-E | Human | Esophagus | ESCC | 2.34e-15 | 3.16e-01 | 0.1177 |
| 51605 | TRMT6 | P4T-E | Human | Esophagus | ESCC | 1.08e-21 | 6.93e-01 | 0.1323 |
| 51605 | TRMT6 | P5T-E | Human | Esophagus | ESCC | 1.20e-09 | 3.25e-01 | 0.1327 |
| 51605 | TRMT6 | P8T-E | Human | Esophagus | ESCC | 7.32e-10 | 2.13e-01 | 0.0889 |
| 51605 | TRMT6 | P9T-E | Human | Esophagus | ESCC | 9.45e-11 | 2.36e-01 | 0.1131 |
| 51605 | TRMT6 | P10T-E | Human | Esophagus | ESCC | 1.77e-17 | 4.59e-01 | 0.116 |
| 51605 | TRMT6 | P11T-E | Human | Esophagus | ESCC | 8.47e-07 | 2.43e-01 | 0.1426 |
| 51605 | TRMT6 | P12T-E | Human | Esophagus | ESCC | 5.75e-13 | 4.08e-01 | 0.1122 |
| 51605 | TRMT6 | P15T-E | Human | Esophagus | ESCC | 7.27e-18 | 4.40e-01 | 0.1149 |
| 51605 | TRMT6 | P16T-E | Human | Esophagus | ESCC | 3.70e-14 | 3.74e-01 | 0.1153 |
| 51605 | TRMT6 | P19T-E | Human | Esophagus | ESCC | 7.81e-06 | 2.81e-01 | 0.1662 |
| 51605 | TRMT6 | P20T-E | Human | Esophagus | ESCC | 1.53e-14 | 5.13e-01 | 0.1124 |
| 51605 | TRMT6 | P21T-E | Human | Esophagus | ESCC | 4.48e-21 | 7.94e-01 | 0.1617 |
| 51605 | TRMT6 | P22T-E | Human | Esophagus | ESCC | 1.24e-15 | 1.96e-02 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001607218 | Oral cavity | LP | rRNA metabolic process | 136/4623 | 236/18723 | 2.37e-27 | 1.48e-24 | 136 |
| GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
| GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
| GO:014005312 | Oral cavity | LP | mitochondrial gene expression | 53/4623 | 108/18723 | 3.54e-08 | 1.27e-06 | 53 |
| GO:00512591 | Oral cavity | LP | protein complex oligomerization | 85/4623 | 238/18723 | 8.81e-05 | 1.11e-03 | 85 |
| GO:00080331 | Oral cavity | LP | tRNA processing | 44/4623 | 127/18723 | 7.50e-03 | 4.15e-02 | 44 |
| GO:003447017 | Skin | cSCC | ncRNA processing | 215/4864 | 395/18723 | 6.83e-34 | 4.28e-31 | 215 |
| GO:003466013 | Skin | cSCC | ncRNA metabolic process | 234/4864 | 485/18723 | 1.37e-26 | 4.77e-24 | 234 |
| GO:004341411 | Skin | cSCC | macromolecule methylation | 107/4864 | 316/18723 | 1.03e-03 | 6.94e-03 | 107 |
| GO:00080334 | Skin | cSCC | tRNA processing | 49/4864 | 127/18723 | 1.20e-03 | 7.81e-03 | 49 |
| GO:00322593 | Skin | cSCC | methylation | 120/4864 | 364/18723 | 1.61e-03 | 9.93e-03 | 120 |
| GO:00063993 | Skin | cSCC | tRNA metabolic process | 64/4864 | 179/18723 | 2.34e-03 | 1.36e-02 | 64 |
| GO:00094513 | Skin | cSCC | RNA modification | 58/4864 | 167/18723 | 7.33e-03 | 3.47e-02 | 58 |
| GO:003447018 | Thyroid | PTC | ncRNA processing | 215/5968 | 395/18723 | 7.14e-21 | 1.22e-18 | 215 |
| GO:00346608 | Thyroid | PTC | ncRNA metabolic process | 239/5968 | 485/18723 | 5.54e-16 | 4.26e-14 | 239 |
| GO:00322594 | Thyroid | PTC | methylation | 146/5968 | 364/18723 | 4.99e-04 | 3.26e-03 | 146 |
| GO:00434145 | Thyroid | PTC | macromolecule methylation | 127/5968 | 316/18723 | 1.02e-03 | 6.07e-03 | 127 |
| GO:003447021 | Thyroid | ATC | ncRNA processing | 216/6293 | 395/18723 | 3.14e-18 | 3.98e-16 | 216 |
| GO:003466021 | Thyroid | ATC | ncRNA metabolic process | 240/6293 | 485/18723 | 2.03e-13 | 9.91e-12 | 240 |
| GO:004341412 | Thyroid | ATC | macromolecule methylation | 131/6293 | 316/18723 | 2.01e-03 | 9.60e-03 | 131 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRMT6 | SNV | Missense_Mutation | rs544190283 | c.712N>T | p.Arg238Trp | p.R238W | Q9UJA5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRMT6 | SNV | Missense_Mutation | c.1439A>C | p.His480Pro | p.H480P | Q9UJA5 | protein_coding | tolerated_low_confidence(0.22) | benign(0) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| TRMT6 | SNV | Missense_Mutation | novel | c.188G>C | p.Gly63Ala | p.G63A | Q9UJA5 | protein_coding | deleterious(0.02) | probably_damaging(0.974) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| TRMT6 | deletion | Frame_Shift_Del | novel | c.607delN | p.Met203Ter | p.M203* | Q9UJA5 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TRMT6 | deletion | Frame_Shift_Del | rs780358338 | c.458delA | p.Lys153AsnfsTer9 | p.K153Nfs*9 | Q9UJA5 | protein_coding | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
| TRMT6 | SNV | Missense_Mutation | c.125G>A | p.Arg42Lys | p.R42K | Q9UJA5 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| TRMT6 | SNV | Missense_Mutation | c.1255G>T | p.Gly419Trp | p.G419W | Q9UJA5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| TRMT6 | SNV | Missense_Mutation | rs766405213 | c.578N>T | p.Thr193Met | p.T193M | Q9UJA5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
| TRMT6 | deletion | Frame_Shift_Del | c.147delN | p.Lys49AsnfsTer20 | p.K49Nfs*20 | Q9UJA5 | protein_coding | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| TRMT6 | deletion | Frame_Shift_Del | rs780358338 | c.458delA | p.Lys153AsnfsTer9 | p.K153Nfs*9 | Q9UJA5 | protein_coding | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |